Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals is a vertically integrated pharmaceutical company committed to deliver high-quality healthcare access to patients across the world.(Source : 201903 Annual Report Page No: 2)

  • Market Cap: 16,421 Cr.
  • Current Price: 871.20
  • 52 weeks High / Low 915.00 / 434.80
  • Book Value: 177.49
  • Stock P/E: 16.79
  • Dividend Yield: 0.80 %
  • ROCE: 23.58 %
  • ROE: 24.82 %
  • Sales Growth (3Yrs): 6.75 %
  • Listed on BSE and NSE
  • Company Website
  • Face Value: 2.00
Edit ratios
Pros:
Company has a good return on equity (ROE) track record: 3 Years ROE 23.58%
Company has been maintaining a healthy dividend payout of 17.45%
Cons:
Company might be capitalizing the interest cost

Peer comparison Sector: Pharmaceuticals // Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Loading peers table ...

Quarterly Results Standalone Figures in Rs. Crores / View Consolidated

Jun 2017 Sep 2017 Dec 2017 Mar 2018 Jun 2018 Sep 2018 Dec 2018 Mar 2019 Jun 2019 Sep 2019 Dec 2019 Mar 2020
590 762 755 838 811 1,095 905 849 897 1,135 1,052 1,049
503 585 594 631 640 746 700 696 672 774 731 752
Operating Profit 87 177 160 207 172 349 205 153 225 361 321 296
OPM % 15% 23% 21% 25% 21% 32% 23% 18% 25% 32% 31% 28%
Other Income 0 8 0 0 0 2 3 1 3 0 0 121
Interest 1 0 1 1 1 5 5 4 5 7 7 7
Depreciation 22 26 26 28 25 26 27 27 32 33 34 36
Profit before tax 64 159 134 179 145 320 177 122 191 322 280 374
Tax % 21% 23% 21% 19% 22% 22% 22% 12% 19% 17% 17% 16%
Net Profit 51 122 105 144 114 251 139 108 155 269 231 314
EPS in Rs 2.69 6.48 5.57 7.65 6.05 13.32 7.35 5.71 8.23 14.25 12.26 16.67
Notes Notes Notes Notes Notes Notes Notes Notes Notes Notes Notes Notes

Profit & Loss Standalone Figures in Rs. Crores / View Consolidated

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 TTM
1,165 1,374 1,493 1,844 2,019 3,009 2,986 2,945 3,660 4,133
1,009 1,166 1,249 1,485 1,611 2,026 2,353 2,313 2,782 2,930
Operating Profit 156 209 244 359 408 983 633 633 879 1,203
OPM % 13% 15% 16% 19% 20% 33% 21% 21% 24% 29%
Other Income 4 13 13 4 3 7 3 7 6 125
Interest 28 38 24 10 3 4 3 2 15 25
Depreciation 30 34 35 40 44 72 83 102 106 136
Profit before tax 102 150 198 312 363 914 550 535 765 1,167
Tax % 20% 20% 21% 24% 21% 24% 22% 21% 20%
Net Profit 82 121 157 238 287 699 431 422 611 969
EPS in Rs 6.17 7.93 12.13 14.49 37.07 22.85 22.39 32.42 51.41
Dividend Payout % 7% 22% 30% 24% 23% 11% 18% 18% 17%
* Sales is net of excise duty and discounts
Compounded Sales Growth
10 Years:%
5 Years:14.70%
3 Years:6.75%
TTM:12.90%
Compounded Profit Growth
10 Years:%
5 Years:20.65%
3 Years:-4.47%
TTM:59.98%
Stock Price CAGR
10 Years:%
5 Years:9.97%
3 Years:17.51%
1 Year:68.15%
Return on Equity
10 Years:%
5 Years:30.17%
3 Years:23.58%
Last Year:24.82%

Balance Sheet Standalone Figures in Rs. Crores / View Consolidated

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
38 38 38 38 38 38 38 38 38 38
Reserves 239 323 422 592 796 1,493 1,830 2,157 2,675 3,308
Borrowings 328 353 187 109 194 0 8 622 1,059 1,687
238 277 352 423 484 651 634 862 777 846
Total Liabilities 816 991 999 1,162 1,511 2,182 2,509 3,678 4,549 5,879
272 268 344 397 489 697 799 918 1,085 1,276
CWIP 26 58 32 21 83 92 348 741 1,107 1,570
Investments 3 3 3 33 33 37 103 299 506 833
514 661 619 711 906 1,355 1,259 1,720 1,850 2,199
Total Assets 816 991 999 1,162 1,511 2,182 2,509 3,678 4,549 5,879

Cash Flows Standalone Figures in Rs. Crores / View Consolidated

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019
105 125 274 263 180 848 327 305 809
-57 -56 -67 -111 -199 -292 -511 -794 -754
-47 -45 -229 -151 18 -276 -96 498 80
Net Cash Flow 1 24 -21 1 -1 280 -280 9 135

Ratios Standalone Figures in Rs. Crores / View Consolidated

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019
ROCE % 28% 33% 47% 41% 72% 32% 23% 24%
Debtor Days 63 50 57 52 61 45 57 77 54
Inventory Turnover 5.75 5.68 6.38 5.82 6.57 5.39 4.73 4.69

Recent announcements

View all announcements

Annual reports

Credit ratings